Ipca Laboratories Limited

BSE:524494 Stock Report

Market Cap: ₹414.2b

Ipca Laboratories Valuation

Is 524494 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524494 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524494 (₹1630.55) is trading above our estimate of fair value (₹680.91)

Significantly Below Fair Value: 524494 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524494?

Key metric: As 524494 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 524494. This is calculated by dividing 524494's market cap by their current earnings.
What is 524494's PE Ratio?
PE Ratio62.6x
Earnings₹6.61b
Market Cap₹414.21b

Price to Earnings Ratio vs Peers

How does 524494's PE Ratio compare to its peers?

The above table shows the PE ratio for 524494 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.5x
AJANTPHARM Ajanta Pharma
43.4x16.3%₹380.2b
GLAND Gland Pharma
43.1x25.8%₹298.3b
506943 J. B. Chemicals & Pharmaceuticals
46.2x19.4%₹282.5b
500660 GlaxoSmithKline Pharmaceuticals
57x16.8%₹384.7b
524494 Ipca Laboratories
62.6x30.1%₹414.2b

Price-To-Earnings vs Peers: 524494 is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the peer average (47.5x).

Price to Earnings Ratio vs Industry

How does 524494's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$72.12m
524652 Ind-Swift
2.8xn/aUS$18.03m
No more companies available in this PE range
524494 62.6xIndustry Avg. 35.0xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 524494 is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the Indian Pharmaceuticals industry average (35x).

Price to Earnings Ratio vs Fair Ratio

What is 524494's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524494 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio62.6x
Fair PE Ratio51.9x

Price-To-Earnings vs Fair Ratio: 524494 is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the estimated Fair Price-To-Earnings Ratio (51.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 524494 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,630.55
₹1,564.37
-4.1%
19.2%₹1,930.00₹900.00n/a19
Dec ’25₹1,543.40
₹1,551.28
+0.5%
19.6%₹1,930.00₹900.00n/a18
Nov ’25₹1,608.50
₹1,425.47
-11.4%
18.9%₹1,950.00₹900.00n/a17
Oct ’25₹1,490.55
₹1,354.89
-9.1%
16.1%₹1,750.00₹900.00n/a18
Sep ’25₹1,383.85
₹1,319.78
-4.6%
14.7%₹1,600.00₹900.00n/a18
Aug ’25₹1,304.80
₹1,215.50
-6.8%
14.4%₹1,438.00₹900.00n/a18
Jul ’25₹1,134.50
₹1,196.94
+5.5%
16.9%₹1,438.00₹687.00n/a18
Jun ’25₹1,152.10
₹1,206.11
+4.7%
17.6%₹1,505.00₹687.00n/a18
May ’25₹1,338.75
₹1,163.11
-13.1%
18.5%₹1,505.00₹687.00n/a18
Apr ’25₹1,238.60
₹1,151.11
-7.1%
14.9%₹1,350.00₹850.00n/a18
Mar ’25₹1,192.65
₹1,139.44
-4.5%
14.5%₹1,350.00₹850.00n/a18
Feb ’25₹1,115.55
₹1,005.61
-9.9%
16.0%₹1,200.00₹670.00n/a18
Jan ’25₹1,119.35
₹992.83
-11.3%
15.0%₹1,200.00₹670.00n/a18
Dec ’24₹1,148.50
₹987.00
-14.1%
15.3%₹1,200.00₹670.00₹1,543.4018
Nov ’24₹979.00
₹899.72
-8.1%
13.9%₹1,200.00₹670.00₹1,608.5018
Oct ’24₹933.00
₹858.89
-7.9%
10.0%₹1,029.00₹670.00₹1,490.5519
Sep ’24₹865.90
₹859.20
-0.8%
9.8%₹1,029.00₹670.00₹1,383.8520
Aug ’24₹902.45
₹826.47
-8.4%
10.3%₹1,010.00₹670.00₹1,304.8019
Jul ’24₹742.20
₹831.56
+12.0%
10.5%₹1,010.00₹670.00₹1,134.5018
Jun ’24₹702.60
₹848.80
+20.8%
12.6%₹1,096.00₹670.00₹1,152.1020
May ’24₹709.65
₹848.80
+19.6%
12.6%₹1,096.00₹670.00₹1,338.7520
Apr ’24₹810.30
₹927.30
+14.4%
9.2%₹1,115.00₹757.00₹1,238.6020
Mar ’24₹807.85
₹929.57
+15.1%
8.8%₹1,096.00₹757.00₹1,192.6521
Feb ’24₹853.55
₹952.29
+11.6%
10.2%₹1,105.00₹757.00₹1,115.5521
Jan ’24₹843.10
₹958.48
+13.7%
10.1%₹1,105.00₹757.00₹1,119.3521
Dec ’23₹865.35
₹963.18
+11.3%
10.0%₹1,105.00₹757.00₹1,148.5022

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 22:13
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ipca Laboratories Limited is covered by 46 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aditya KhemkaAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited
Sanjeev ChiniwarAnand Rathi Shares and Stock Brokers Limited